Haematological Malignancies Articles & Analysis
11 articles found
Cancer treatment has witnessed transformative advancements over the past few decades, notably with the emergence of CAR-T (Chimeric Antigen Receptor T-cell) therapy. This revolutionary therapy harnesses the body's immune system by genetically engineering T-cells to target and destroy cancer cells. Among the pioneering companies at the forefront of this innovation is Alfa Cytology, renowned for ...
Fluorescence In Situ Hybridization (FISH) and Immunohistochemistry (IHC) are two powerful techniques widely used in biological and medical research. While each has its strengths, the combination of these methods—ImmunoFISH—offers a unique and comprehensive approach to investigation at the cellular and tissue levels. Understanding the Techniques FISH is primarily utilized for detecting ...
ESMO updated its recommendations for NGS in advanced cancers this year, urging broader use of NGS in additional cancer types and the inclusion of tumor-agnostic biomarkers. The ESMO Precision Medicine Working Group (PMWG) first published its recommendations for when to use next-generation sequencing (NGS) in routine practice for patients with metastatic cancers in 20201. At that time, based ...
Coupling drugs combine the precise targeting and potent killing properties, has become a widely recognized form of medication in recent years. Radioactive drug conjugates (RDCs), as a particular form of coupling drugs, are formed by combining radioactive isotopes with disease-targeting molecules. According to the application of RDCs, they can be divided into two main categories: diagnostic RDCs ...
Thymic Stromal Lymphopoietin (TSLP) is a multifunctional cytokine that acts on various cell types, including dendritic cells, T cells, B cells, neutrophils, mast cells, eosinophils, and innate lymphoid cells, affecting their maturation, survival, and recruitment. It is well-known for its role in promoting type 2 immune responses, such as allergic diseases. In 2021, a monoclonal antibody targeting ...
Antibody-drug conjugates (ADCs) usually consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs via chemical linkers. With high specific targeting ability and strong killing effect, it has achieved precise and efficient removal of cancer cells, and has become one of the hot spots in the development of anticancer drugs. In 2000, the FDA first approved the ADC drug Mylotarg ...
The advent of immunotherapies for cancer, and more recently of cellular immunotherapies, has substantially altered the treatment landscape. In hematological malignancies, complete response rates to CAR-T cells can exceed 80%. These responses are often durable in nature and have attracted considerable excitement and investment in the development of cell therapies for an expanded range of ...
Celdara Medical, LLC today announced that the National Cancer Institute of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) Phase I award to fund the company’s proof of concept studies on a new platform to improve chimeric antigen receptor (CAR) T cells efficacy to treat solid tumors. Dr. Joana Murad-Mabaera, who leads this effort, stated, ...
Glycoprotein prostaglandin D2 synthase (PTGDS) is a member of the lipocalcitonin superfamily that plays a dual role in prostaglandin metabolism and lipid transport. PTGDS is involved in various cellular processes including solid tumorigenesis, but its role in tumorigenesis is paradoxical, and the significance of PTGDS in hematologic malignancies is not clear. The aim of this new study was to ...
As a kind of enzymes for diagnostic use. Serum amylase (AMS) is the main type of amylase in serum. It belongs to glycoside chain hydrolase, which is mainly derived from the pancreas. In addition, there are also a small amount of secretion in the proximal duodenum, lung, uterus, and breast during lactation. Amylase plays an important role in the digestion of polysaccharide compounds in food. The ...
Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity CD1d can be expressed by several hematologic malignancies Bispecific Vγ9Vδ2-T cell engager Unique ability to also trigger type 1 natural killer T (NKT) ...